OPT Quote, Financials, Valuation and Earnings

Immutep has a net margin of -- compared to Opthea's net margin of --. Opthea's return on equity of -- beat Immutep's return on equity of --.

Opthea has a consensus price target of $12.17, signalling upside risk potential of 212.37%. On the other hand Immutep has an analysts' consensus of -- which suggests that it could grow by 392.23%. Given that Immutep has higher upside potential than Opthea, analysts believe Immutep is more attractive than Opthea.

Opthea has a beta of 0.710, which suggesting that the stock is 29.036% less volatile than S&P 500. In comparison Immutep has a beta of 2.197, suggesting its more volatile than the S&P 500 by 119.655%.

Opthea has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immutep offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Opthea pays -- of its earnings as a dividend. Immutep pays out -- of its earnings as a dividend.

Opthea quarterly revenues are --, which are smaller than Immutep quarterly revenues of --. Opthea's net income of -- is lower than Immutep's net income of --. Notably, Opthea's price-to-earnings ratio is -- while Immutep's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Opthea is 2,492.46x versus -- for Immutep. Usually stocks with elevated PS ratios are considered overvalued.

Immuron has a net margin of -- compared to Opthea's net margin of --. Opthea's return on equity of -- beat Immuron's return on equity of -40.9%.

Opthea has a consensus price target of $12.17, signalling upside risk potential of 212.37%. On the other hand Immuron has an analysts' consensus of -- which suggests that it could grow by 132.59%. Given that Opthea has higher upside potential than Immuron, analysts believe Opthea is more attractive than Immuron.

Opthea has a beta of 0.710, which suggesting that the stock is 29.036% less volatile than S&P 500. In comparison Immuron has a beta of 1.376, suggesting its more volatile than the S&P 500 by 37.636%.

Opthea has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immuron offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Opthea pays -- of its earnings as a dividend. Immuron pays out -- of its earnings as a dividend.

Opthea quarterly revenues are --, which are smaller than Immuron quarterly revenues of --. Opthea's net income of -- is lower than Immuron's net income of --. Notably, Opthea's price-to-earnings ratio is -- while Immuron's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Opthea is 2,492.46x versus 3.81x for Immuron. Usually stocks with elevated PS ratios are considered overvalued.

Kazia Therapeutics has a net margin of -- compared to Opthea's net margin of --. Opthea's return on equity of -- beat Kazia Therapeutics's return on equity of -1083.16%.

Opthea has a consensus price target of $12.17, signalling upside risk potential of 212.37%. On the other hand Kazia Therapeutics has an analysts' consensus of -- which suggests that it could grow by 1312.2%. Given that Kazia Therapeutics has higher upside potential than Opthea, analysts believe Kazia Therapeutics is more attractive than Opthea.

Opthea has a beta of 0.710, which suggesting that the stock is 29.036% less volatile than S&P 500. In comparison Kazia Therapeutics has a beta of 2.117, suggesting its more volatile than the S&P 500 by 111.748%.

Opthea has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kazia Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Opthea pays -- of its earnings as a dividend. Kazia Therapeutics pays out -- of its earnings as a dividend.

Opthea quarterly revenues are --, which are smaller than Kazia Therapeutics quarterly revenues of --. Opthea's net income of -- is lower than Kazia Therapeutics's net income of --. Notably, Opthea's price-to-earnings ratio is -- while Kazia Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Opthea is 2,492.46x versus -- for Kazia Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Mesoblast has a net margin of -- compared to Opthea's net margin of --. Opthea's return on equity of -- beat Mesoblast's return on equity of --.

Opthea has a consensus price target of $12.17, signalling upside risk potential of 212.37%. On the other hand Mesoblast has an analysts' consensus of $11.00 which suggests that it could grow by 30.06%. Given that Opthea has higher upside potential than Mesoblast, analysts believe Opthea is more attractive than Mesoblast.

Opthea has a beta of 0.710, which suggesting that the stock is 29.036% less volatile than S&P 500. In comparison Mesoblast has a beta of 3.357, suggesting its more volatile than the S&P 500 by 235.658%.

Opthea has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mesoblast offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Opthea pays -- of its earnings as a dividend. Mesoblast pays out -- of its earnings as a dividend.

Opthea quarterly revenues are --, which are smaller than Mesoblast quarterly revenues of --. Opthea's net income of -- is lower than Mesoblast's net income of --. Notably, Opthea's price-to-earnings ratio is -- while Mesoblast's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Opthea is 2,492.46x versus 179.39x for Mesoblast. Usually stocks with elevated PS ratios are considered overvalued.